In the first four months of 2020, the budget segment of the Russian medicine market increased by 48%, reaching 200.8 billion rubles. Cancer drugs have remained the main growth driver since 2019 as AlphaRM shared on June 17 at the online conference “Russian Pharmaceutical Market: From 2020 to 2030”.
The state-controlled segment was the principal contributor to the medicine market dynamics throughout the period under review. In comparison, the commercial segment grew by just 12% in monetary terms, climbing to 375 billion rubles.
The analysis of the budget medicine market was based on a number of variables including the clinical segment, preferential drug provision (PDP) and the target segment. PDP accounted for over 54% of the total budget segment. The clinical segment (outpatient clinics, hospitals as well as maternal and child healthcare facilities) were responsible for about 31% of supplies, which totaled 61.8 billion rubles (57% more than in the same period in 2019). Finally, the target segment (federal and regional target programs) increased by 198% to almost 30 billion rubles.
The top 5 manufacturers in the government segment were Pharmstandard (8.4% of the market), Biokad (5.1%), Sanofi (5%), Novartis (4.9%) and SG Biotech (4.7%). The medication Revlimid emerged as the market leader although its sales displayed a downward trend compared to the same period in 2019 (-21%). Darzalex of Johnson & Johnson showed the highest growth rate (+2472%).